Drug name - Cinvanti

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808465 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof Sep, 2035

(12 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof Sep, 2035

(12 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant Sep, 2035

(12 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof Sep, 2035

(12 years from now)

Drugs and Companies using APREPITANT ingredient

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
130MG/18ML (7.2MG/ML) EMULSION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.